Document
IPR2023-00724, No. 2477 Exhibit - EX2477 US Food Drug Administration, DrugsFDA, Brenzavvy (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2477 Exhibit - EX2477 US Food Drug Administration, DrugsFDA, Brenzavvy (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2398 Exhibit - EX2398 Januvia® Prescribing Information rev Feb 2018 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2398 Exhibit - EX2398 Januvia® Prescribing Information rev Feb 2018 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1041 Exhibit - WO136 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1041 Exhibit - WO136 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1042 Exhibit - WO457 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1042 Exhibit - WO457 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1003 Exhibit - Bantle Decl (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1003 Exhibit - Bantle Decl (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1306 Exhibit - Exhibit 1306 Coca Decl (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1306 Exhibit - Exhibit 1306 Coca Decl (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1065 Exhibit - Tasneem 2012 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1065 Exhibit - Tasneem 2012 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1153 Exhibit - Exhibit 1153 Edwards 2004 (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1153 Exhibit - Exhibit 1153 Edwards 2004 (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1158 Exhibit - Exhibit 1158 Novo Press Release (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1158 Exhibit - Exhibit 1158 Novo Press Release (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2431 Exhibit - EX2431 US Food Drug Administration, DrugsFDA, Oseni® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2431 Exhibit - EX2431 US Food Drug Administration, DrugsFDA, Oseni® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2060 Exhibit - EX2060 Rosenstock, J, et al, “The Fate of Taspoglutide, a Weekly GLP 1 Receptor Agonist, Versus Twice Daily Exenatide for Type 2 Diabetes,” Diabetes Care...
Cite Document
IPR2023-00724, No. 2060 Exhibit - EX2060 Rosenstock, J, et al, “The Fate of Taspoglutide, a Weekly GLP 1 Receptor Agonist, Versus Twice Daily Exenatide for Type 2 Diabetes,” Diabetes Care, Vol36, 49
+ More Snippets
Document
IPR2023-00724, No. 2064 Exhibit - EX2064 Synapse, “Pegylated GLP 1 analogue LY2428757 – Eli Lilly Co,” available at httpssynapsepatsnapcomdrug482a547adeba4170ab23efa225fb966d l...
Cite Document
IPR2023-00724, No. 2064 Exhibit - EX2064 Synapse, “Pegylated GLP 1 analogue LY2428757 – Eli Lilly Co,” available at httpssynapsepatsnapcomdrug482a547adeba4170ab23efa225fb966d last updated December
+ More Snippets
Document
IPR2023-00724, No. 2062 Exhibit - EX2062 Rosenstock, J, et al, “Potential of Albiglutide, a Long Acting GLP 1 Receptor Agonist, in Type 2 Diabetes,” Diabetes Care, Vol32, Issue 10, 1880 1886...
Cite Document
IPR2023-00724, No. 2062 Exhibit - EX2062 Rosenstock, J, et al, “Potential of Albiglutide, a Long Acting GLP 1 Receptor Agonist, in Type 2 Diabetes,” Diabetes Care, Vol32, Issue 10, 1880 1886 October
+ More Snippets
Document
IPR2023-00724, No. 1135 Exhibit - Exhibit 1135 40th Orange Book (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1135 Exhibit - Exhibit 1135 40th Orange Book (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1121 Exhibit - Exhibit 1121 833 patent (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1121 Exhibit - Exhibit 1121 833 patent (P.T.A.B. May. 22, 2024)
+ More Snippets